DelveInsight’s, “Anaplastic Thyroid Cancer Pipeline Insight 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge. A recent review published in Genes & Diseases offers a ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab to conventional multimodal therapy shows significant benefits in reducing the recurrence ...

Support for the study of anaplastic thyroid carcinoma came from Genentech, the Rare Tumor Initiative, the University of Texas MD Anderson Cancer Center, and NIH.

We report herein the case of an 87-year-old woman presenting with a rapidly growing thyroid mass in whom the differential diagnosis of anaplastic cancer was challenging. Following work up, the patient ...

SUMMARY Collision tumors are rare and may comprise components with different behavior, treatments, and prognosis. We report an unprecedented case of aggressive thyroid collision tumor containing ...

Notably, a metabolic complete response (mCR) was achieved in one patient with anaplastic thyroid cancer (ATC), the most aggressive form of the disease.

Anaplastic thyroid cancer is a rare and fast-growing disease. Learn what causes it and its symptoms, diagnosis, and treatments.

Overall survival rates for adults diagnosed with anaplastic thyroid carcinoma are similar between those with a history of cancer and those with no previous cancer diagnosis, according to findings ...

Background: Both anaplastic thyroid carcinoma (ATC) and thyroid lymphoma (TL) clinically present as rapidly enlarging neck masses. Unfortunately, in this situation, like in any other thyroid swelling, ...

The use of immune checkpoint inhibitors in anaplastic thyroid cancer shows a similar toxicity profile to that seen in PD-1 and PD-L1 targeting therapies.